Moving on to greener pastures.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If it didn't happen in April it sure happened last week on the day that 32% of the shares were traded. I would assume that somebody new now owns at least 10% of the company and will have to come forward by next week and file a 13D or 13G document with the SEC.
https://www.sec.gov/fast-answers/answerssched13htm.html
Perhaps it was a friendly party who purchased the shares last week. Maybe management knew that was going to happen but couldn't comment Let the buyer get 10% or more of the company for a bargain so that it makes their future capital infusion easier as they will then already own 10% or more of the company at a good PPS.
Making it easier to buy more of MannKind later at a higher price by a tender offer.
The reporting is required within 10 days. I do not know if that is business day or calendar days. If calendar days that would be either Saturday or Sunday.
The potential buyer could also have a deal with the Mann Foundation to purchase their shares at a much higher price in the future. The Foundation does not want to cut and run and probably has not yet done so. Their goal is to see the company survive and Al's legacy of Afrezza change lives.
So with that in mind the potential suitor makes the investment into the company with MannKind having to do any further dilution.
I did not attend the meeting today. I was there last year. We had a very open question and answer period. The allow all the questions or statements to be asked that shareholder presented.
I learned from a person in attendance today. That Matt limited his comments. That they did not allow a question and answer period with most thought was strange. My GUESS is that they limited or eliminated that Q & A as they didn't want any questions to be asked that might have be related to the share actions of the last 10 trading days.
Since I'm only an investor it makes me wonder what is really going on as management has always been pretty open by either email or in person.
Maybe we learn more this weekend or before the market opens on Monday.
Yep i bet Amazon would know how to market an OTC afrezza. You see that Human Insulin can be sold OTC. It's not a drug. Generic human insulin is available that way today. MannKind would have 24-7 hour service on how to use the product and tie that into Apple / Android apps and One Touch
It allows PWD to take care of their own needs. While it would not be for 100% of the patients as some have more complications than others. Sold directly to the consumer. You can bet that Big Pharma would try to crush this effort and try to get the FDA to prevent but the FDA changed this rule in 2012. It allows for the same of Human Insulin direct to consumers with out a prescription.
Half the diabetics in America don't have access to Insulin or its too expensive to buy it even with Insurance. Direct to Consumer would be cheap and easy as its the PBM distribution system that creates the current pricing mechanisms.
Could the RLS project really be the investment by Amazon and others in trying to bring this project forward.
Last week Mike Castagna posted a picture from Seattle which was about a mile form Amazon HQ. It was a cute picture of a car that was tricked out by the owner. I wondered if it was a wink and a smile from Mike.
Local deliver points and why kill the retail pharma location 100%. Right now Amazon deliveries go to Fed ex holding boxes at Walgreens stores. They will know how to monetize the retail store locations.
Not to Cash rich Amazon who will just give out some more stock and make the deal happen fast.
I got a couple of thousand shares today at 3.38 per share. Helped me to average down. To under 5.00. I'm happy. Deal goes with WBA great or if not the next deal with Amazon will be the best one.
I would gladly take $10.00 from Amazon in stock it would be ok too.
Amazon will pay and close the deal very fast so its a win / win for the shareholders.
Will the FTC scuttle this deal with WBA? I bet not. I do hope they kill the deal. The next one will be better for the shareholders of Rite Aid.
Hypo it be a fun meeting to attend if something pre-market was announced. I guess we will see SHORTLY.
It will be priced on opportunity over future years of sales when properly marketed by a financially sound company.
First with domestic sales and later with international sales.
Afrezza works. Diabetes is a worldwide epidemic that is a slow killer.
Good post! But a divorce from WBA would be ok to if our new Groom was Amazon
Amazon wants in Pharmacy business
White knight for Rite Aid.
http://www.cnbc.com/2017/05/17/amazon-could-break-open-the-pharmacy-space-steve-kraus-bessemer.html
Amazon could 'break open' the pharmacy space, says health tech investor
Health investor Steve Kraus is not surprised that Amazon is considering a push into the pharmacy market.
He sees huge opportunities for Amazon to compete with the biggest pharmacies.
Kraus says Amazon should go full throttle, rather than carve out one slice of the market.
"Amazon could break open the space," said Steve Kraus, a health investor with Bessemer Venture Partners.
For Kraus, Amazon's potential move into the pharmacy space, which CNBC reported on Tuesday, is not surprising. In his view, every major technology company should have a play in health care, an estimated $3 trillion sector.
For Amazon, the obvious move is to sell prescription drugs online.
In the wake of the news, shares of pharmacy stocks such as CVS and Walgreens Boots Alliance opened lower. But industry experts think these companies aren't the only ones that should be worried about Amazon's entrance into the space.
Kraus thinks it could be a blow to a slew of on-demand drug delivery startups, such as New York's Zipdrug. The pharmacies themselves might also face some new competition, including the big players and the "mom and pop" stores, he said.
"Look at what Amazon has done to malls," Kraus added. "In the future, when people say they're going to a Walgreens or CVS, they might instead choose to go to Amazon.com."
Others say it could be a threat to the pharmacy benefits managers, such as Express Scripts and CVS, which control consumer access.
But TJ Parker, CEO and co-founder of PillPack, a mail-order pharmacy that butt heads with Express Scripts, said Amazon entering the market might force these players to build a more customer-friendly user experience. "Without many serious competitors or true threats, these services have been stagnant for more than 20 years," he said
Amazon could start small, by targeting consumers without insurance or high-deductible plans. It might borrow the model of a company like GoodRx, which often quotes far lower prices on prescription drugs that pharmacies will often charge out-of-pocket.
But Kraus suspects that Amazon will go bigger than that. The company "might crawl, walk and then run," he says, but ultimately he predicts that if it does move forward, it won't restrict itself to one part of the chain. Instead, Amazon could work directly with manufacturers, become a distributor like McKesson, take on the role of a pharmacy benefits manager by negotiating discounts and sell drugs to patients as a licensed pharmacy.
He even suspects that Amazon could get more competitive prices on drugs, if it could fill drugs faster and demonstrate that patients are more likely to take their meds.
"In Amazon style, it will want to own the consumer's mind and wallet," Kraus adds.
In other words, go big or go home.
Watch: Why wouldn't Amazon go into pharmaceuticals?
Let the deal fall apart, get the breakup fee from Walgreens and then get married to Amazon with announced today they wanted to go full steam ahead in become a player in the PBM pharmacy business.
The RAD PBM would be a great entry point for Amazon. They have plenty of money and will pay very quickly $10.00 per share on. Either cash or Amazon shares. That would be a good deal. What could FTC regulators say or do?
Only sorry I didn't buy more when it was in the $300.00 range.
What are you talking about! You don't make any sense
Do you think there might be something big happening prior to the Shareholders meeting.
Do you think there is a 13D or 13G filing made prior to the Shareholders meeting on Thursday .
That would make for interesting drama with the newly surfaced shareholder asking to have a board seat.
There is something going on that will surface this week.
Schedule 13D
www.sec.gov/fast-answers/answerssched13htm.html
Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities registered under Section 12 of the Securities Exchange Act of 1934, they are required to file a Schedule 13D with the SEC. (Depending upon the facts and circumstances, the person or group of persons may be eligible to file the more abbreviated Schedule 13G in lieu of Schedule 13D.)
Schedule 13D reports the acquisition and other information within ten days after the purchase. The schedule is filed with the SEC and is provided to the company that issued the securities and each exchange where the security is traded. Any material changes in the facts contained in the schedule require a prompt amendment. The schedule is often filed in connection with a tender offer.
You can find the Schedules 13D for most publicly traded companies in the SEC’s EDGAR database. You can learn how to use EDGAR to find information about companies.
Something is up.
It's arbitrage deal somebody has been accumulating shares. (Who)
The company may finally have an activist investor who is about to be revealed.
Perhaps hostile to current management and aegis was hired by Management to convince shareholders to hang tough with management.
SEC Legal filings to show 10% or more ownership released the next day or two,or the morning of the shareholder meeting.
You don't see the heavy churning we saw last week if something wasn't going on. 32 million shares on Wed. Over 70 million shares churned last week? Why?
Last year we had Henry Orlasky make his proposal. But he didn't control enough shares to get the board
attention. But now perhaps somebody has got enough shares and will reveal themselves in the next 48 to 72 hours. A
Great story and I think in time $MDT will own Mazor. I also own $ISRG love it and have held since 2010.
Look at this other Robotic company trading very cheap. $CVRS Corindus Vascular Robotics. They are just starting to Monetize their robotic equipment.
I got burned on Titan Robotics. so I don't like them.
You know of any other good Robotic Companies?
Look for a this up and coming company $CHEK Check-Cap. Its an Israeli company developing a specialized Camera to replace Colonoscopy procedures.
Nice reply and lets hope that Value Line is correct. that target is a nice one.
More on the One Drop relationship to UAE.
http://onedrop.today/blog/2016/12/15/one-drop-announces-partnership-national-health-insurance-company-daman-uaes-leading-specialized-health-insurer-implementation-one-drop-professional-enterprise-pl/
Company announces partnership with The National Health Insurance Company – Daman, the UAE’s leading specialized health insurer, making comprehensive diabetes care available to more than 3 million members in the UAE via the One Drop | Professional enterprise platform.
December 15, 2016 — New York — One Drop today announced that The National Health Insurance Company – Daman (“Daman”), the UAE’s largest and most innovative health insurer, has chosen One Drop to lead its digital and mobile health innovation efforts in diabetes.
One Drop’s enterprise solution, One Drop | Professional, has been implemented by Daman to empower its members living with diabetes to monitor and take charge of their health through easy-to-use, accessible technology. One Drop | Professional is a population health management platform that fosters real-time interactions between people with diabetes and their healthcare teams. With One Drop | Professional, members track their health data and receive personalized health coaching through the One Drop | Mobile platform. Care providers are able to view members’ health data in real-time and provide relevant, highly personalized education and support in the context of everyday life, which is when these interactions are needed most.
“We are committed to using the most innovative technology to expand quality and effectiveness of care, and through our partnership with One Drop we expect to make great strides in diabetes management and outcomes,” said Dr. Michael Bitzer, Chief Executive Officer at Daman. “One Drop’s platform offers a way to fill the gap between clinic visits, allowing for the continuity of care necessary for people with diabetes to get and stay healthy.”
One Drop | Professional has been adapted for Daman based on a thorough understanding of the social habits, lifestyles and culture of the people of the UAE. The One Drop | Mobile experience has been enhanced to include special features for Daman members, including Arabic language support, region-specific food data, a 9-week lesson plan, and curated content via the in-app news feed. Daman members also have access to premium features that allow them to communicate with Daman health coaches to get the information and support needed for improved blood glucose management.
Over the past few decades, rapid economic growth across the Middle East has led to a rapid change of lifestyle and a corresponding increase in the rates of diabetes in the region. Today, the Middle East and North Africa (MENA) have the highest prevalence of diabetes in the world, with nearly 35 million people (1 in every 10) diagnosed. According to the International Diabetes Federation, 19.3 percent of adults ages 20 to 79 in the United Arab Emirates have diabetes, and it is among of the leading causes of premature death. Spending on diabetes care in the MENA region is estimated to rise from $16.8 billion in 2014 to $24.7 billion in 2035, threatening to impact economics and bankrupt healthcare systems.
Governments and healthcare providers have recognized the severity of epidemic and, beginning in 2009, the UAE government rolled out a ten-year plan to fight the disease including increased diabetes research, public awareness campaigns, and updated medical facilities. Daman is taking an innovative approach by using mobile technology to move care beyond the clinic and into people’s everyday lives. One Drop | Professional combines the use of real-time data and human support to empower people to take ownership of their diabetes management in a way that is motivating, encouraging, and long-lasting. Daman members are able to see the relationship between their behaviors and blood sugars each day and, with the continuous support of their coach, effect positive behavioral change and avoid long-term complications.
“Daman is an ideal partner for implementing One Drop | Professional, given its focus on providing members with smart choices and the highest possible level of support, comfort and convenience when it comes to healthcare.” said Jeff Dachis, Founder and Chief Executive Officer of One Drop. “The UAE is among the countries facing the highest diabetes rates in the world. Our collective goal is to provide affordable, accessible, and effective evidence-based care to improve outcomes for the people who need it most.”
About The National Health Insurance Company – Daman
The National Health Insurance Company – Daman is the UAE’s leading specialized health insurer, providing comprehensive health insurance solutions to more than 3 million members in the UAE. Over the years, the company has been the partner of choice for a number of the country’s most prominent organizations and multinational companies in various industries including oil and gas, aerospace, energy, construction, investments and media.
Daman is a public joint-stock company that is 80% owned by the Abu Dhabi Government with the remaining 20% owned by Munich Re. The company is backed by the reliable support of the Abu Dhabi Government and its strategic partner, Munich Re, one of the world’s leading reinsurers, plays an important role as both reinsurer and a valuable source for knowledge transfer.
Headquartered in Abu Dhabi and established in 2006, Daman offers a range of health insurance plans for both individuals and organizations and exclusively manages the Government’s health program, Thiqa, for UAE Nationals and Abu Dhabi Basic Plan for low income expatriates. Members enjoy access to the largest healthcare providers’ network in the UAE and an extensive international network of over 45 countries.
Daman, a pioneer in health care insurance, drives innovation through a combination of state-of-the-art technology and healthcare-related expertise offered by a highly skilled and knowledgeable workforce. Members benefit from added value through unique offerings such as the disease and case management programs as part of the acclaimed Health Support services. Daman also operates a 24/7 customer call center and has a medical services authorization team in direct contact with Daman’s network of healthcare providers. It also provides a diverse range of online services that are unmatched in the UAE.
Daman has set high standards in the health insurance industry and has been awarded a number of internationally recognized awards and quality-focused certifications in a relatively short span of time. The company is ISO 9001 certified for Quality Management Systems.
Have to wonder about the One Drop relationship with MannKind. There is a Tie In to the Abu Dhabi UAE Healthcare system.
So MannKind and One Drop will be a partner potentially in the UAE.
This will be interesting to see how it plays out.
Daman is a non-life insurance conventional health insurance government-affiliated company in Abu Dhabi, United Arab Emirates. It started operations in May 2006, with over 1000 employees. Mohammed Sultan bin Ghanoum Al Hameli is the chairman and Dr. Michael Bitzer is the CEO of Daman. Daman offers a range of health insurance plans with added benefits, extended policy limits and wider geographical coverage. Daman is a public joint-stock company that is 80% owned by the Abu Dhabi Government with the remaining 20% owned by the Germany based Munich Re. With the highest market share in Abu Dhabi, Daman covers more than 2,600,000 members
One Drop & Daman
http://mhealth.ae/onedrop/
------------------------------------------------------
VALENCIA, Calif. and NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) TASE:MNKD) and One Drop today announced that they have signed a memorandum of understanding to enter into a collaborative agreement that would extend One Drop’s subscription service and digital health platform – which currently provides unlimited blood glucose testing supplies and 24/7 live in-app support from diabetes experts – by adding Afrezza as a rapid-acting insulin offering.
The planned collaboration will include three consumer-focused areas:
1.Access, Cost Savings and Convenience initiatives, intended to simplify the complexity of starting and staying on mealtime insulin.
2.Customized Coaching and Engagement designed to help people on Afrezza achieve the American Diabetes Association (ADA) recommendation of an A1C goal of less than 7%.
3.Design innovation around packaging and exploration of a reusable Afrezza Inhaler with integrated Bluetooth technology.
“Against a backdrop of soaring insulin costs, this proposed collaboration is an essential step in the right direction,” said Jeff Dachis, CEO and Founder of One Step. “One Drop began with the goal of bringing affordable, accessible diabetes care to everyone living with diabetes worldwide. Through this partnership with MannKind, we will continue to work tirelessly to empower everyone with diabetes to achieve better health outcomes through the use of modern delivery methods that reduce the burden of diabetes management and increase engagement in self-care.”
“The complexity and conflicting incentives of the United States healthcare system are not aligned to help people with diabetes on insulin achieve optimal outcomes, as we see that almost seven out of ten people on mealtime insulin are not at the ADA goal of <7% A1C,” said Michael Castagna, Chief Commercial Officer of MannKind Corporation. “Even though injectable insulins have been available for decades, 20% of users regularly skip injections. We intend to empower people with diabetes to take charge of their health by trying something different.”
“We believe that diabetes care as a fully integrated digital service is the only way that we are going to bend the cost curve for payers and providers, while at the same time delivering evidence-based health outcomes that can scale,” continued Dachis. “Working with an innovator like MannKind, with a clinically effective, non-invasive inhaled mealtime insulin product, offers up an exciting opportunity to further our mission of relentlessly improving the lives of everyone with diabetes and a smartphone.”
One Drop recently presented findings from a retrospective study demonstrating that One Drop | Mobile app users report a substantial improvement in blood glucose levels, reducing A1c by 1.0 percentage point (8.2% to 7.2%) after only 2 to 12 months of using One Drop | Mobile.[1]
One Drop has also shared preliminary data collected from people with diabetes using One Drop | Mobile and One Drop | Experts for just four consecutive weeks, showing that One Drop users:
reduced average blood glucose by 27 mg/dL;
• reduced average blood glucose from 185 mg/dL (A1c 8.1%) to 158 (A1c 7.1%);
• reduced average percentage of high blood glucose readings from 19% to 4%;
• nearly doubled the percentage of in-range blood glucose readings; and
• consistently tracked food and blood glucose over time.[2]
In the next few months, One Drop will present the complete results of several clinical studies conducted over the past year. Altogether, One Drop | Mobile users have contributed more than 280 million primary health data points, which One Drop analyzes to deliver powerful insights that drive improved health outcomes for people with diabetes, as well as immediate proven cost-savings for both people with diabetes and their care providers.
“Our approach is to advance traditional therapies by delivering better access to scalable care, better education, more convenience, lower costs, and an improved user experience,” said Dachis. “Ultimately, we must deliver results. There is too much at stake for business as usual.”
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
_______________
1 Osborn, C. Y., et al. (2017, March). One Drop App Users Report Improved Glycemic Control. Poster session presented at the Society of Behavioral Medicine 38th Scientific Sessions, San Diego, CA.
2 Osborn, C. Y., et al. (2017, March). The One Drop | Mobile App and Experts Program is Evidence-based and Improves Blood Glucose. Poster session presented at the Society of Behavioral Medicine 38th Scientific Sessions, San Diego, CA.
3 The American Diabetes Association recognizes this education service as meeting the National Standards for Diabetes Self-Management Education and Support.
About One Drop
One Drop (Informed Data Systems Inc.) is a digital health company harnessing the power of mobile computing and data science to transform the lives of everyone with diabetes.
One Drop's offerings include the first-ever monthly subscription service to provide clinically effective, affordable, accessible diabetes care. For less than the cost of a monthly co-pay, One Drop subscribers receive:
•One Drop | Chrome with Unlimited Testing Supplies: One Drop | Chrome not only meets the highest standards of clinical accuracy, but also wirelessly transmits blood glucose data directly to the cloud via the One Drop | Mobile app for iOS and Android. Unlimited blood glucose test strips are delivered on-demand directly to the doors of One Drop subscribers — no prescriptions, no insurance, no appointments, and no hassles.
•One Drop | Experts for Anytime Care: One Drop | Experts moves diabetes education out of the clinic and into the lives of people with diabetes. Each One Drop | Premium subscriber has his/her own “Expert” (Certified Diabetes Educator) available 24/7 for guidance, support, and anytime care. Experts deliver personalized digital therapeutics programs, including ADA-recognized diabetes education[3], to help people with diabetes define and achieve their health management goals. Subscribers can communicate with their Experts anytime via in-app chat; all data recorded in the app is available to Experts in real-time, allowing them to provide relevant behavioral guidance in the moments when subscribers need it most. No appointments necessary.
•One Drop | Mobile: One Drop | Mobile is an award-winning, cloud-based diabetes management solution delivered entirely via mobile app on iOS and Android. One Drop | Mobile provides real-time and historical blood glucose data and analytics to subscribers and their healthcare providers, allowing both to see relationships between specific health behaviors and health outcomes. One Drop | Mobile also includes a fully-featured Apple WatchOS app for logging and analyzing diabetes data on the go. One Drop | Mobile is the only diabetes management platform that offers comprehensive self-care, peer-support, and expert support all in one place.
One Drop also offers an enterprise solution, One Drop | Professional, for insurers, health care provider networks, and self-insured employers to dramatically lower the cost of caring for people with diabetes.
The One Drop | Mobile solution is available for free worldwide. One Drop | Chrome is sold exclusively by One Drop (iOS, Android, and http://onedrop.today/), Amazon (http://www.amazon.com), and Apple (http://store.apple.com). One Drop's consumer subscription service is available for purchase in-app (iOS and Android) and at http://onedrop.today. For more information, contact just@onedrop.today.
Love my McDonald's. $1.00 coffee sure is better than $5.00 at Five Bucks. That is why we have seen MCD move from $90.00 to $145.36. Missed out on Panera Bread but glad to have been in MCD for 8 years.
Can't wait to see where Edwards goes the next 12 months.
Surprised nobody is watching Edwards on this site. I invested back in 2013 and only wished I was smart enough to have bought more in the last year. I see EW eventually back to the 120.00 area before the end of 2017.
As the sales develop and the $MDT sales team gets more involved this is a stock worth $50.00 by the 4th quarter assuming they make the sales.
MDT has the ability to buy a bigger % of the shares of Major and can do that now or before December 2017. So it would not be a surprise that MDT eventually owns the entire company. But that assumes that sales grow and the company has to hiccups in production.
Good advice with the TREND we are on lately. MannKind needs investors with the patience of Job.
I guess we won't know till the fat lady sings. Sometimes the next owner does better and will monetize the product.
Since you and others have written the company off you should just move along and find another board with great upside. There are thousands of them without the risk of MannKind.
The TREND is horrible than you should move on. Sitting here day after day in misery is a very Negative TREND. Perhaps you remain to see the anguish of investors like myself who can't see the way out of MannKind you have.
I need some prayers to help me find a positive TREND. Martin will you pray for me and we both have kept the faith on what seems to be a hopeless path with no way out of the Abyss.
Martin I got this neat yellow post card today. Actually 4 of them. I would guess that all the shareholders have been sent the cards. Something about recent developments with regards to MannKind.
I will have to check this out Monday.
HYPI I think your correct as the folks I know have noticed the same vibrations of things to come. Many of the shareholders I know are in the big share camp. They are not stressed out about the current PPS. On the contrary they are adding shares.
Sales might be slow but management is focused on organic growth and they have positive signals its progressing.
You can't do an ultraMarathon without training and that starts with 5K races and progressing forward. Afrezza is not for the complacent diabetic. It's for the diabetic who wants to take control of their life and treatment. the doctors don't push patients to new drugs as it its not broke don't fix it.
New patients will be advocates for their own healthcare like WHS. He figured out what he wanted. In time others will adapt to Afrezza. As that happens there will be a rise in scripts. It won't be overnight
My guess is when they do market they will target to folks under 40 who have busy schedules and compliance issues. Travelers and busy people.
The Reversed TV program will give some visibility and Charles Mattocks is well connected.
Go out and read about active Type 1 diabetics like Robin Arzon who is best known as the Peleton lady. She leads an active life style with T1D while she is not on Afrezza to my knowledge that is the type of consumer that will eventually put MannKind in the Black. Patients who TAKE CHARGE OF THEIR HEALTH. ACTIVISTS FOR THEIR OWN CARE.
Something is up when you have 70,000,000 shares trade in a week.
Wed volume of 32,000,000 shares is 32% of the total shares.
The product works as WHS stated and the world will be waiting for Afrezza.
I purchased more shares today with a limit order. It took 30 mins to fill and 42 individual tranches in sizes from 15 shares to 1600 shares each. Glutton for punishment or foolish perhaps but then again who knows what is going to happen.
The Trend will eventually turn positive. You can sit back and not take risks as some on this board have done or you can put it on the line.
Afrezza work and will be a paradigm shift in the diabetes marketplace.
Tick tick tick KABOOM!
Correct this can be a great story. It will take years to develop. I would target it to double within 12 months. Don't expect much more than that to occur.
Perhaps 18 months.
Better then the guy who didn't buy it.
He didn't want to be a trendsetter.
Disclosure:
I am 74 years old
Never taken a long nor short position in
The proprietary value is probably closer to about $30 per share. Based on today's known issues and future value. That might be a stretch but it would be fair market value. I would rather see a 50% owner in than selling my shares
Martin said this will trade based on potential future value not today's measly numbers.
On pace to do 30 million volume today. There is serious blood in the water. Something is going on.
30 million is equal to 30% of outstanding shares.
At the end of the fourth hour 16 million shares traded in that is an average of 67,400 shares per minute
Martin is correct! It's the value that could be monetized once sales take off and distribution channels are opened up.
This is not a domestic insulin this will be an insulin available worldwide in time. Hey real paradigm shift for treating diabetes.
It takes most new drugs 3 to 5 years before gaining sales. Sadly we had a setback because of the Sanofi debacle.
Great story posted about usage of the equipment.
http://www.prweb.com/releases/2017/05/prweb14316176.htm
Allegheny Health Network Physicians Perform Pennsylvania’s First Robotic-Assisted Spine Surgeries Using Innovative Technology
Share Article
Pioneering Mazor X™ System Provides Minimally Invasive Treatment Option for Debilitating Spine Conditions, Offered Exclusively at Allegheny General, Forbes and Saint Vincent Hospitals
PITTSBURGH, PA. (PRWEB) MAY 09, 2017
Surgeons at Allegheny Health Network (AHN) have become the first in Pennsylvania to perform robotic-assisted, minimally invasive spine surgery using a sophisticated, new technology called the Mazor X™ system. The first procedure was performed at Allegheny General Hospital (AGH) by Donald Whiting, MD, Chair of AHN’s Neuroscience Institute.
The Mazor X system utilizes enhanced analytical tools, precision guidance, optical tracking, and intra-operative verification capabilities to make spine surgery safer and less invasive for patients. The technology combines a suite of pre-operative analytics software designed to assess spinal alignment and implement computerized 3D surgical planning. Intra-operative guidance is provided to surgeons through a robotic surgical arm designed to guide tools and synergistic implants according to the pre-operative analytics.
"Our surgical team is among the most experienced and skilled in the country for the treatment of injuries to the spine,” said Dr. Whiting. "Mazor X greatly enhances the capabilities of our surgeons to help us achieve the best possible outcomes for patients undergoing spine surgery, including less post-operative pain, fewer complications and a quicker recovery. We are extremely pleased to be able to exclusively offer this innovative surgical option to patients in the western Pennsylvania region.”
The Mazor X system can be used to treat a host of conditions like spinal stenosis, scoliosis and spondylolisthesis that often cause debilitating symptoms, such as low back pain, leg pain and sciatica.
The technology can improve outcomes from spinal fusion procedures, or the process of fusing two or more vertebrae together to create a single continuous bone. Used to treat broken vertebrae, spinal deformities or spinal instability, surgeons often implanted metallic plates, screws or rods to hold and graft the bone to promote healing. An estimated 500,000 Americans undergo the procedure each year for low back pain alone.
According to Dr. Whiting, spinal fusion has traditionally been done using an open technique in which patients are susceptible to larger incisions and scars, increased blood loss, and longer hospital stays.
While less invasive techniques have helped minimize the trauma of surgery, many intraoperative X-rays are typically required without a guidance system to compensate for a surgeon’s compromised visualization.
Among its many potential benefits, the Mazor X system promises to reduce the risk of exposure to radiation from X-ray imaging typically used during surgery.
Compared to conventional open spine procedures, Mazor Robotics reports that patients who have undergone minimally invasive surgery with its technology experienced a 27 percent reduced average length of hospital stay, a 48 percent less complication rate, and a 46 percent reduced need for a revision procedure.
"The ability to pre-plan a patient’s spine surgery using Mazor X’s sophisticated 3D software allows us to create the ideal procedure for every patient’s individualized condition. It’s an optimal approach to treating patients who suffer from a variety of spine disorders, and enables us to help more patients recover sooner and return to their daily activities without the pain and discomfort that they previously faced,” said Terrence Julien, MD, a neurosurgeon at Forbes Hospital who is using the Mazor X system.
Other AHN physicians who will use the Mazor X technology include neurosurgeons Michael Oh, MD, David Oliver-Smith, MD, Richard Prostko, MD, Nestor Tomycz, MD, Brian Dalton, MD, and Daniel Muccio, MD; orthopaedic surgeons Daniel Altman, MD, and Gary Schmidt, MD; and pediatric orthopaedic surgeon Mark Sangimino, MD.
The addition of the Mazor X system builds upon AHN’s legacy of innovation in robotic-assisted surgery.
In 2015, orthopaedic surgeons at West Penn Hospital were the first to perform robotic-assisted total-hip and partial-knee replacements using the MAKO Robotic Arm Interactive Orthopaedic system. MAKO, which facilitates unprecedented accuracy in joint replacement, is exclusively available in the region at AHN’s Allegheny General, West Penn, Forbes, Saint Vincent and Jefferson hospitals.
AGH doctors were also at the forefront of using the da Vinci Robotic Surgical System in the early 2000s and currently use the pioneering technology at various hospitals to perform minimally invasive abdominal, urologic, gynecologic and cardiac procedures.
"Surgical care at AHN has long entailed the use of the leading-edge technologies and procedures across a range of specialties,” said Dr. Whiting. "Adding Mazor X to our world-class neurosurgical and orthopedic programs demonstrates that AHN remains committed to making investments in technology that yield tremendous benefits for the health and safety of the patients we care for.”
###
About the Neuroscience Institute at AHN
AHN’s Neuroscience Institute integrates leading medical experts in the subspecialties of neurology, neuro-otology, neuro-ophthalmology, neuroradiology, neuro-critical care, and neurosurgery to offer highly advanced care for patients with the most complex neurological disorders. Recognized as both a Neuroscience Center of Excellence and a Spine Center of Excellence, the program serves as a national and international referral center for treatment of all types of neurological conditions.
That 20 Million shares really is about 100,000 shares pre-reverse split. Think about that number for a bit. Something is up.
With the big volume of shares traded on Monday and Tuesday each day was about 10% of the outstanding shares. I would not surprise me if somebody was buying 5% or 10% interest in the company. I guess we will learn whenever somebody makes a filing.
Yep! Martin that is the trend of some is to play games
If the Trend is that bad why do some stick around if they didn't have an agenda. Martin is an investor and not a day trader. Investors have multiple positions and they are disciplined in how they approach there investments.
I agree with 100% of what you said.
Agree and here are some of the developments we might hear on Wednesday and at annual meeting next week:
1.) New labeling with fast acting.
2.) JDRF update and tell me children wouldn't want the ability to deliver insulin thru the dreamboat
3.) Financing and partner
4.) International partner and development
5.) New show, commercials and advertising
6.) New spokesperson maybe Nick Jonas or another celebrity
7.) New applications
8.) RLS and VDEX update
Big list and we will hear a lot on Wednesday. Shorts will fry this week.
Martin I agree 100%. This is about the future of diabetes treatment. Very difficult to see with the poor financial situation. Investors in BIO have seen this situation over and over again.
MannKind has an FDA approved drug. It will be monetized either by the current owner of the company or the next owner. It takes guts to hang around as an investor as it could go bankrupt and you lose 100% or they struggle by and eventually they start turning it around.
Been investing for over 45 years and this one has been the company with the most possibility to make it really big if it survives. While I have invested more dollars in this one than some of the 40 or more positions that I currently own I still am not upset about it being a loser or writing it off. I have had to sell some during 2016 to offset capital gains I had with other opportunities. That was ok as i was able to get back in at a very low cost per shares. Why did I rebuy the shares? It's because of the potential that Mannkind has to be a real game changer for Diabetic treatment and a very good investment.
Only time will tell what happens. It might take 3 to 5 years before we really know.